Exclusion criteria encompassed studies related to sensory neuropathy, multiple sclerosis, diabetic neuropathy, fibromyalgia, post-surgical pain, cancer pain, and other non-cancer pain causes, as well as studies involving cannabinoid mimetic interventions such as palmitoylethanolamide and fatty acid amide hydrolase (FAAH) inhibitors. The gene discussed is FAAH; the disease is diabetic neuropathy.